Keywords
Last Name

Joshua D. Safer, MD

TitleAssociate Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionEndocrinology, Diabetes & Nutrition
Address85 E. Newton St Fuller Building
Boston MA 02118
Phone(617) 638-8530
ORCID ORCID Icon0000-0003-2497-8401
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Graduate Medical Sciences

 Research Expertise & Professional Interests
Expertise includes: Thyroid Hormone Action; Thyroid Hormone Molecular Biology; Thyroid Disease; Thyroid Cancer Treatment; Thyroid Hormone Action on Skin; Wound Healing Physiology; Wound Healing Molecular Biology; Androgen Action; Sex Hormone Treatment Strategies; Transgender Treatment.

 NIH RePORTER Grants

Yr Title Project-Sub Proj Pubs
2000 CENTRAL RESISTANCE TO THYROID HORMONE 5K08DK002423-05 4
1999 CENTRAL RESISTANCE TO THYROID HORMONE 7K08DK002423-04 4


 Self-Described Keywords
  • Androgen Action
  • Androgens
  • Cutaneous
  • Dermis
  • Epidermis
  • Sex Hormone Treatment
  • Skin
  • Thyroid
  • Thyroid Cancer Treatment
  • Thyroid Disease
  • Thyroid Hormone
  • Thyroid Hormone Action
  • Thyroid Hormone Action on Skin
  • Thyroid Hormone Molecular Biology
  • Transgender
  • Wound Healing Molecular Biology
  • Wound Healing Physiology
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Gardner IH, Safer JD. Progress on the road to better medical care for transgender patients. Curr Opin Endocrinol Diabetes Obes. 2013 Dec; 20(6):553-8.
    View in: PubMed
  2. Safer JD, Pearce EN. A simple curriculum content change increased medical student comfort with transgender medicine. Endocr Pract. 2013 Jul-Aug; 19(4):633-7.
    View in: PubMed
  3. Safer JD. Transgender medical research, provider education, and patient access are overdue. Endocr Pract. 2013 Jul-Aug; 19(4):575-6.
    View in: PubMed
  4. Safer JD. Thyroid hormone and wound healing. J Thyroid Res. 2013; 2013:124538.
    View in: PubMed
  5. Safer JD. Thyroid hormone action on skin. Curr Opin Endocrinol Diabetes Obes. 2012 Oct; 19(5):388-93.
    View in: PubMed
  6. Kannan S, Safer JD. Finding the right balance between resistance and sensitivity: a review of the cardiac manifestations of the syndrome of resistance to thyroid hormone and the implications for treatment. Endocr Pract. 2012 Mar-Apr; 18(2):252-5.
    View in: PubMed
  7. Toraldo G, Bhasin S, Bakhit M, Guo W, Serra C, Safer JD, Bhawan J, Jasuja R. Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking ß-catenin nuclear translocation and cross-talk with TGF-ß signaling in keratinocytes. Wound Repair Regen. 2012 Jan-Feb; 20(1):61-73.
    View in: PubMed
  8. Leung AM, Safer JD. Thyrotoxicosis of extra thyroid origin. Werner and Ingbar's The Thyroid. Lippincott Williams and Williams. Philadelphia. 2012; 429-433.
  9. Huang MP, Rodgers KA, O'Mara R, Mehta M, Abuzahra HS, Tannenbaum AD, Persons K, Holick MF, Safer JD. The thyroid hormone degrading type 3 deiodinase is the primary deiodinase active in murine epidermis. Thyroid. 2011 Nov; 21(11):1263-8.
    View in: PubMed
  10. Choong K, Safer JD. Graves disease and gynecomastia in 2 roommates. Endocr Pract. 2011 Jul-Aug; 17(4):647-50.
    View in: PubMed
  11. Safer JD. Thyroid hormone action on skin. Dermatoendocrinol. 2011 Jul; 3(3):211-5.
    View in: PubMed
  12. Abraham TM, de las Morenas A, Lee SL, Safer JD. In thyroid fine-needle aspiration, use of bedside-prepared slides significantly increased diagnostic adequacy and specimen cellularity relative to solution-based samples. Thyroid. 2011 Mar; 21(3):237-42.
    View in: PubMed
  13. Ariza MA, Loken WM, Pearce EN, Safer JD. Male sex, African American race or ethnicity, and triiodothyronine levels at diagnosis predict weight gain after antithyroid medication and radioiodine therapy for hyperthyroidism. Endocr Pract. 2010 Jul-Aug; 16(4):609-16.
    View in: PubMed
  14. Bhasin S, Safer J, Tangpricha V. The Hormone Foundation’s patient guide to the endocrine treatment of transsexual persons. Journal of Clinical Endocrinology and Metabolism. 2009; 94(9).
  15. Safer JD, Persons K, Holick MF. A thyroid hormone deiodinase inhibitor can decrease cutaneous cell proliferation in vitro. Thyroid. 2009 Feb; 19(2):181-5.
    View in: PubMed
  16. Feldman J, Safer J. Hormone therapy in adults: Suggested revisions to the sixth version of the Standards of Care. International Journal of Transgenderism. 2009; 3(11):146-182.
  17. Pietras SM, Safer JD. Diagnostic confusion attributable to spurious elevation of both total thyroid hormone and thyroid hormone uptake measurements in the setting of autoantibodies: case report and review of related literature. Endocr Pract. 2008 Sep; 14(6):738-42.
    View in: PubMed
  18. Safer JD, Tangpricha V. Out of the shadows: it is time to mainstream treatment for transgender patients. Endocr Pract. 2008 Mar; 14(2):248-50.
    View in: PubMed
  19. Safer JD, Holick MF. Potential therapeutic uses of thyroid hormone. Thyroid Disorders with Cutaneous Manifestations, Heymann WR, ed. Springer-Verlag. London, UK. 2008; 181-186.
  20. Safer JD, Ray S, Holick MF. A topical parathyroid hormone/parathyroid hormone-related peptide receptor antagonist stimulates hair growth in mice. Endocrinology. 2007 Mar; 148(3):1167-70.
    View in: PubMed
  21. Saha AK, Persons K, Safer JD, Luo Z, Holick MF, Ruderman NB. AMPK regulation of the growth of cultured human keratinocytes. Biochem Biophys Res Commun. 2006 Oct 20; 349(2):519-24.
    View in: PubMed
  22. Safer JD, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. Endocrinology. 2005 Oct; 146(10):4425-30.
    View in: PubMed
  23. Safer JD, Hennessey JV, Braverman LE. Substituting brand name levothyroxine preparations with generics would increase treatment cost. Annals of Internal Medicine. 2005.
    View in: External Website
  24. Safer JD. The skin and connective tissue in hypothyroidism. Werner and Ingbar’s The Thyroid, 9th Edition, Braverman LE and Utiger RD, eds. Lippincott Williams and Williams. Philadelphia, PA. 2005; 769-773.
  25. Safer JD. The skin in thyrotoxicosis. Werner and Ingbar’s The Thyroid, 9th Edition, Braverman LE and Utiger RD, eds. Lippincott Williams and Williams. Philadelphia, PA. 2005; 553-558.
  26. Safer JD, Crawford TM, Holick MF. A role for thyroid hormone in wound healing through keratin gene expression. Endocrinology. 2004 May; 145(5):2357-61.
    View in: PubMed
  27. Santini F, Vitti P, Chiovato L, Ceccarini G, Macchia M, Montanelli L, Gatti G, Rosellini V, Mammoli C, Martino E, Chopra IJ, Safer JD, Braverman LE, Pinchera A. Role for inner ring deiodination preventing transcutaneous passage of thyroxine. J Clin Endocrinol Metab. 2003 Jun; 88(6):2825-30.
    View in: PubMed
  28. Safer JD, Crawford TM, Fraser LM, Hoa M, Ray S, Chen TC, Persons K, Holick MF. Thyroid hormone action on skin: diverging effects of topical versus intraperitoneal administration. Thyroid. 2003 Feb; 13(2):159-65.
    View in: PubMed
  29. Safer JD. Resistance to Thyroid Hormone. Contemporary Endocrinology: Diseases of the Thyroid, 2nd Edition, Braverman LE, ed. Humana Press Inc. Totowa, NJ. 2003; 199-216.
  30. Koutkia P, Safer JD. Adrenal metastasis secondary to papillary thyroid carcinoma. Thyroid. 2001 Nov; 11(11):1077-9.
    View in: PubMed
  31. Tangpricha V, Chen BJ, Swan NC, Sweeney AT, de las Morenas A, Safer JD. Twenty-one-gauge needles provide more cellular samples than twenty-five-gauge needles in fine-needle aspiration biopsy of the thyroid but may not provide increased diagnostic accuracy. Thyroid. 2001 Oct; 11(10):973-6.
    View in: PubMed
  32. Safer JD, Fraser LM, Ray S, Holick MF. Topical triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. Thyroid. 2001 Aug; 11(8):717-24.
    View in: PubMed
  33. Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid. 2001 Mar; 11(3):281-91.
    View in: PubMed
  34. Safer JD, O'Connor MG, Colan SD, Srinivasan S, Tollin SR, Wondisford FE. The thyroid hormone receptor-beta gene mutation R383H is associated with isolated central resistance to thyroid hormone. J Clin Endocrinol Metab. 1999 Sep; 84(9):3099-109.
    View in: PubMed
  35. Safer JD, Cohen RN, Hollenberg AN, Wondisford FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem. 1998 Nov 13; 273(46):30175-82.
    View in: PubMed
  36. Langlois MF, Zanger K, Monden T, Safer JD, Hollenberg AN, Wondisford FE. A unique role of the beta-2 thyroid hormone receptor isoform in negative regulation by thyroid hormone. Mapping of a novel amino-terminal domain important for ligand-independent activation. J Biol Chem. 1997 Oct 3; 272(40):24927-33.
    View in: PubMed
  37. Safer JD, Langlois MF, Cohen R, Monden T, John-Hope D, Madura J, Hollenberg AN, Wondisford FE. Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone. Mol Endocrinol. 1997 Jan; 11(1):16-26.
    View in: PubMed
  38. Safer JD, Wondisford FE. TSH, Normal Physiology. Contemporary Endocrinology: Diseases of the Pituitary, Wierman ME, ed. Humana Press Inc. Totowa, NJ. 1997; 283-293.
Joshua's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_